Hemanext ONE is the first meaningful FDA-authorized processing and storage technology proven to mitigate the red blood cell (RBC) storage lesion.1-4

Transforming Red Blood Cells  Advancing Care.TM

Hemanext is a global biomedical technology pioneer in transfusion medicine. We recognize the vital role of blood for patients and are committed to optimizing its therapeutic impact and value to the healthcare system. Focused on the study of hypoxically stored RBCs, our research and development efforts aim to significantly improve the quality of stored RBCs worldwide. We strive to achieve our mission of delivering innovations that improve the standard of care for patients who rely on transfusions by transforming RBCs through protecting their quality, functionality, and viability during storage.

Latest News and Events

Hemanext Research

Learn more about Hemanext and take a closer look at our publications, studies, and posters focused on blood quality and red blood cell characterization.

Worldwide Patent Assets

Accepted Scientific Abstracts

Total Publications